Related by context. All words. (Click for frequent words.) 65 Malignant gliomas 65 gliomas 63 glioblastoma multiforme GBM 62 glioblastoma 62 epithelial tumors 62 Glioblastomas 62 grade gliomas 61 glioblastomas 61 pancreatic NET 61 GISTs 60 Glioblastoma multiforme GBM 60 Gliomas 60 non metastatic osteosarcoma 60 pancreatic adenocarcinoma 60 astrocytomas 59 Follicular lymphoma 59 renal carcinoma 59 Glioblastoma 59 osteosarcomas 59 Myelofibrosis 59 metastatic kidney 58 neuroendocrine cancers 58 Chronic lymphocytic leukemia 58 metastatic GIST 58 Hepatocellular Carcinoma HCC 58 Basal cell 58 gastrointestinal stromal tumors 58 myelofibrosis polycythemia vera 58 leukaemias 58 Acute lymphoblastic leukemia 58 colorectal liver metastases 58 ADPKD 58 Acute myeloid leukemia 58 gastrointestinal stromal tumor GIST 58 gastric cancers 58 malignancies 58 histologic subtype 58 carcinomas 57 essential thrombocythemia 57 neuroendocrine tumors 57 standard chemotherapy regimens 57 idiopathic myelofibrosis 57 medullary thyroid cancer 57 follicular lymphoma 57 differentiated thyroid 57 ependymoma 57 leukemia ALL 57 solid tumors 57 colorectal cancer CRC 57 nonsmall cell lung cancer 57 GBMs 57 biliary tract cancer 57 stage IIIA 57 metastatic lesions 57 carcinoid 57 myeloproliferative neoplasms 57 Kit CD# positive 57 unresectable tumors 57 KRAS wild 57 invasive ductal 57 PCNSL 57 relapsed SCLC 57 renal cell carcinoma 56 seminoma 56 hematologic cancers 56 systemic fungal infections 56 Myelodysplastic syndromes MDS 56 candidemia 56 breast carcinomas 56 nonmelanoma skin cancers 56 hepatocellular carcinoma 56 heavily pretreated 56 leukemia APL 56 Squamous 56 Leber congenital amaurosis LCA 56 glioma tumors 56 renal tumors 56 GBM tumors 56 malignant pleural mesothelioma 56 hematologic malignancies 56 metastatic melanoma 56 anaplastic astrocytoma 56 chronic lymphocytic leukemia CLL 56 metastatic renal cell carcinoma 56 Chronic Lymphocytic Leukemia CLL 56 operable breast cancer 56 glioma 56 Hurthle cell 56 indolent lymphoma 56 relapsing remitting 56 Pancreatic neuroendocrine tumors 56 squamous cell carcinoma SCC 56 Leukemias 56 completely resected 56 preoperative chemotherapy 56 hepatitis C genotype 56 Carcinoid tumors 56 EGFR mutations 56 prostate adenocarcinoma 56 pancreatic cancers 56 carcinoid tumors 56 skeletal metastases 56 glioblastoma multiforme 56 NOMID 56 Glioblastoma Multiforme GBM 56 recurrent glioblastoma multiforme 56 anaplastic 56 squamous cell 56 acute myeloid 56 mesotheliomas 56 chronic myeloid leukemia CML 56 hepatocellular carcinomas 56 bladder cancers 56 squamous cell lung cancer 56 oligodendrogliomas 56 renal cell carcinomas 56 K ras mutations 56 metastatic RCC 56 Follicular Lymphoma 56 Philadelphia Chromosome Positive 55 Gleevec resistant 55 anti angiogenic therapy 55 hepatocellular cancer 55 homozygous familial hypercholesterolemia 55 Chronic myeloid leukemia CML 55 lymphomas 55 recurrent glioblastoma 55 HNSCC 55 Anaplastic 55 ovarian breast 55 malignant brain 55 inherited retinal degeneration 55 HER2 positive metastatic breast 55 grade glioma 55 grade cervical intraepithelial 55 myelodysplastic syndrome MDS 55 recurrent NSCLC 55 stage IIIB IV 55 postoperative pathology 55 recurrent glioblastoma multiforme GBM 55 squamous cell cancer 55 gastric adenocarcinoma 55 PNH patients 55 MPS IVA 55 Hurler syndrome 55 cancers 55 serous ovarian cancer 55 metastatic cancer 55 adenocarcinoma 55 glial tumors 55 acute lymphoid leukemia 55 cervical carcinoma 55 sarcomatoid 55 ANCA associated 55 castrate resistant prostate cancer 55 cytogenetic responses 55 meningiomas 55 rituximab refractory 55 squamous 55 ovarian tumors 55 basal cell carcinoma BCC 55 Renal Cell Carcinoma RCC 55 intracranial hemorrhage ICH 55 cytogenetic response 55 familial pancreatic cancer 55 leukemia AML 55 histologies 55 B CLL 55 Basal cell carcinoma 55 malignant glioma 55 HER2 positive cancers 55 squamous cell cancers 55 bladder tumors 55 hematopoietic cancers 55 metastatic renal cell 54 prostate cancers 54 smoldering myeloma 54 myeloproliferative disorders 54 oligodendroglioma 54 histological subtypes 54 hepatorenal syndrome 54 acute leukemias 54 nasopharyngeal carcinoma 54 myelofibrosis 54 adrenocortical cancer 54 acute myeloid leukemia AML 54 tumors GIST 54 Relapsing remitting MS 54 mucinous 54 pancreatic carcinoma 54 glioblastoma GBM 54 KRAS mutations occur 54 malignant neoplasm 54 hematologic disorders 54 ErbB2 positive 54 HER2 + 54 familial adenomatous polyposis 54 chronic granulomatous disease 54 Papillary 54 indolent NHL 54 subependymal giant cell 54 histological subtype 54 tumor histology 54 BRAF mutation 54 liver metastasis 54 malignant pheochromocytoma 54 medulloblastoma 54 Glioblastoma multiforme 54 TTF Therapy 54 gastrointestinal cancers 54 pancreatic tumors 54 squamous cell carcinomas 54 acute lymphoblastic 54 nonmetastatic 54 tyrosine kinase inhibitors 54 follicular lymphoma FL 54 hematologic malignancy 54 ependymomas 54 non squamous NSCLC 54 papillary 54 neurodegenerative disorder 54 BRAF V# mutation 54 seminomas 54 leukemias 54 chronic myeloid 54 Idiopathic Pulmonary Fibrosis IPF 54 recurrent GBM 54 tumors 54 hematological diseases 54 proliferative diabetic retinopathy 54 Acute myeloid leukemia AML 54 HER2 expression 54 refractory CML 54 Chronic lymphocytic leukemia CLL 54 Endometrial cancer 54 Hodgkin lymphoma HL 54 gastrointestinal stromal tumor 54 HER2 negative 54 superficial bladder cancer 54 radiosensitive 54 lung adenocarcinomas 54 inherited neurodegenerative disorder 54 malignancy 54 ASCUS 54 gastric carcinoma 54 medulloblastomas 54 recurrent colorectal cancer 54 pituitary adenomas 54 pancreatic neuroendocrine 53 Venous thromboembolism 53 poorer prognosis 53 endometrial cancers 53 soft tissue sarcomas 53 JMML 53 Chronic myeloid leukemia 53 erlotinib Tarceva ® 53 refractory NSCLC 53 hepatocellular carcinoma HCC 53 Metastatic melanoma 53 nasopharyngeal cancer 53 geographic atrophy 53 relapsing remitting MS RRMS 53 hematopoietic malignancies 53 Ph + ALL 53 unresectable 53 pCR 53 testicular cancers 53 Metastatic 53 metastatic neuroendocrine tumors 53 Sjögren syndrome 53 metastatic cancers 53 AAT deficiency 53 pancreatic lung 53 Relapsed Refractory 53 HER2 overexpression 53 advanced hepatocellular carcinoma 53 lung adenocarcinoma 53 B7 H3 53 Tay Sachs thalassemia 53 chronic myelogenous leukemia CML 53 invasive lobular carcinoma 53 myeloproliferative diseases 53 bronchogenic carcinoma 53 acute myelogenous leukemia AML 53 lung pancreatic 53 leukemia CLL 53 haematologic 53 basal cell nevus syndrome 53 pilocytic astrocytomas 53 HER2 positive 53 GIST 53 hepatic encephalopathy HE 53 frontotemporal dementia 53 Idiopathic pulmonary fibrosis 53 stage IIIB 53 brain tumors 53 cutaneous melanoma 53 CYT# potent vascular disrupting 53 castrate resistant 53 hamartomas 53 NSCLC 53 neuroblastomas 53 familial amyloidotic polyneuropathy FAP 53 leukemias lymphomas 53 vWD 53 diabetes mellitus DM 53 peritoneal carcinomatosis 53 situ CIS 53 primary immunodeficiency 53 grade serous ovarian 53 de novo AML 53 Chronic sinusitis 53 gastrointestinal stromal tumors GIST 53 idiopathic pulmonary fibrosis IPF 53 chronic HBV infection 53 systemic lupus erythematosus SLE 53 acute GvHD 53 oncoproteins 53 CIN3 53 metastatic bladder 53 underwent brachytherapy 53 Hereditary angioedema HAE 53 underwent resection 53 non squamous histology 53 imatinib resistance 53 dyskeratosis congenita 53 T#I mutation 53 cutaneous squamous cell carcinoma 53 relapsing remitting MS 53 GIST tumors 53 Medullary thyroid cancer 53 Renal cell carcinoma 53 autoantibody positive 53 metastatic disease 53 EGFR mutation positive 53 allogeneic stem cell 53 mutated KRAS gene 53 lymphocytic leukemia 53 refractory anaplastic astrocytoma 53 KRAS mutation 53 HbF 53 imatinib Gleevec 53 hypereosinophilic syndrome 53 epileptic syndromes 53 AA Amyloidosis 53 adenomatous polyps 53 lung metastases 52 multiple myeloma MM 52 haematologic malignancies 52 TTR amyloidosis 52 non squamous 52 MCyR 52 neoplasms 52 Tumors shrank 52 elevated triglyceride levels 52 cisplatin resistant 52 colorectal carcinoma 52 panobinostat 52 familial ALS 52 carcinoma 52 urothelial cancer 52 systemic scleroderma 52 Median survival 52 lung carcinomas 52 refractory acute myeloid 52 ovarian lung 52 malignant melanomas 52 papillary renal cell carcinoma 52 chemoembolization 52 HER2 positive breast cancer 52 ovarian endometrial 52 adverse cytogenetics 52 SOD2 gene 52 metastatic brain tumor 52 malignant lesions 52 metastatic lung cancer 52 acute promyelocytic leukemia 52 eosinophilic asthma 52 ovarian carcinoma 52 Sezary syndrome 52 daunorubicin 52 bowel cancers 52 precancerous cervical lesions 52 hyperoxaluria 52 myelofibrosis MF 52 graft dysfunction 52 metastatic malignant melanoma 52 myelodysplastic syndromes 52 Metastatic colorectal cancer 52 Meningiomas 52 breast cancer subtypes 52 malignant pancreatic 52 metastatic gastric 52 EoE 52 Colon polyps 52 bone metastasis 52 transplantation HCT 52 irinotecan chemotherapy 52 colorectal lung 52 untreated celiac disease 52 anaplastic astrocytoma AA 52 histologic diagnosis 52 imatinib resistant 52 mRCC 52 steatohepatitis 52 common hematologic malignancy 52 curable cancers 52 Myelodysplastic syndromes 52 Major depressive disorder 52 liver metastases 52 resectable 52 Cutaneous T 52 CIN2 + 52 bronchopulmonary dysplasia BPD 52 dasatinib Sprycel 52 BRCA mutations 52 trans retinoic acid ATRA 52 recurrent ovarian cancer 52 ER CHOP 52 pelvic malignancies 52 Celiac disease affects 52 Waldenstrom macroglobulinemia 52 Hodgkin lymphoma NHL 52 pan HDAC inhibitor 52 Polycythemia vera 52 indolent lymphomas 52 MALT lymphoma 52 Exacerbations 52 Bladder cancer 52 juvenile myelomonocytic leukemia 52 brain metastases 52 bladder carcinoma 52 Platinol ® cisplatin 52 fatal neuromuscular disorder 52 metastatic renal 52 biochemical recurrence 52 heterozygous FH 52 ccRCC 52 pleural mesothelioma 52 Chronic Myelogenous Leukemia CML 52 malignant tumors 52 relapsed leukemia 52 Velculescu 52 allogeneic transplants 52 Glioma 52 prostate carcinoma 52 Barrett esophagus 52 thymoma 52 dysplastic nevi 52 malignant cancerous 52 stage IIIb IV 52 ovarian cancers 52 colorectal carcinomas 52 Tamibarotene 52 malignant pleural mesothelioma MPM 52 Mantle Cell Lymphoma 52 metachronous 52 Surgical resection 52 lobular cancer 52 prognostic variables 52 Parkinsonian Syndromes 52 gastrointestinal tumors GIST 52 HNPCC 52 EGFR mutation 52 progressive neurodegenerative disorder 52 lymphoma CTCL 52 Stomach cancer 52 LHRH receptor positive 52 DLBCL 52 adenoma 52 uveal melanoma 52 relapsed MM 52 muscular dystrophies 52 Lymphomas 52 refractory chronic myeloid 52 CMV infection 52 refractory chronic lymphocytic 52 relapsed refractory multiple myeloma 52 Severe Primary IGFD 52 adenocarcinomas 52 paragangliomas 52 chronic ITP 52 prostate cancer PCa 52 primary immunodeficiencies 52 sorafenib Nexavar ® 52 colorectal adenocarcinoma 52 essential thrombocythemia ET 52 HGPIN 51 melanoma lesions 51 lupus nephritis 51 glioblastoma tumors 51 metastatic malignant 51 Lung transplantation 51 bladder ovarian 51 molecular subtypes 51 oropharyngeal cancer 51 haematological cancers 51 PsA 51 follicular lymphomas 51 EGFR inhibitors 51 nonalcoholic steatohepatitis NASH 51 sarcomas 51 mutated KRAS 51 invasive cervical cancer 51 metastatic melanomas 51 Bronchiectasis 51 metastatic tumors 51 cell acute lymphoblastic 51 resected pancreatic cancer 51 inherited mutations 51 mutated K ras 51 metastatic pancreatic cancer 51 1 diabetes T1D 51 partial remissions 51 Imatinib 51 colorectal neoplasms 51 lymphoproliferative disorders 51 epithelial cancers 51 astrocytoma 51 MAGE A3 51 Gastrointestinal Stromal Tumors 51 castration resistant prostate cancer 51 latent TB infection 51 distant metastasis 51 pulmonary hypertension PH 51 prostate cancer CaP 51 clinically localized prostate 51 follicular non 51 cell carcinoma 51 hematological 51 p# biomarker 51 lobular carcinoma 51 Multiple myeloma 51 lobular carcinomas 51 DIPG 51 Wilms tumor 51 BRCA2 mutations 51 MGUS 51 colon cancers 51 ruptured aneurysms 51 FOLFOX4 51 nasopharyngeal carcinoma NPC 51 colon pancreas 51 Pancreatic cancer 51 atherosclerotic lesions 51 severe malignant osteopetrosis 51 lymphocytic 51 advanced NSCLC 51 IIIB NSCLC 51 hA# 51 HCV infections 51 generalized epilepsy 51 Uterine fibroids 51 pancreatic cysts 51 malignant fibrous histiocytoma 51 neoadjuvant radiation 51 thyroid nodules 51 breast cancers 51 hepatitis C HCV 51 advanced metastatic renal 51 osteoporotic vertebral fractures 51 pemphigus vulgaris 51 AA amyloidosis 51 benign moles 51 anterior uveitis 51 Acute Promyelocytic Leukemia 51 TEAEs 51 cervical lesions 51 Diffuse Large B 51 locoregional 51 hepatic metastases 51 CLL cells 51 Cholangiocarcinoma 51 molecular abnormalities 51 mycosis fungoides 51 symptomatic BPH 51 frequently benign tumor 51 unresectable stage 51 standard chemotherapy regimen 51 breast cancer susceptibility genes 51 neoplasm 51 WT1 51 cutaneous T cell 51 pathogenic mutations 51 hormone deprivation 51 malignant lymphomas 51 advanced carcinoid 51 inherited metabolic disorders 51 trans retinoic acid 51 supratentorial 51 metastatic colon cancer 51 mCRC 51 MYCN amplification 51 atypical hemolytic uremic syndrome 51 progesterone receptor negative 51 metastatic colorectal cancer 51 radiation chemoradiation 51 prostate carcinomas 51 locoregional recurrence 51 Glioblastoma Multiforme 51 alveolar rhabdomyosarcoma 51 hormone refractory metastatic prostate 51 tubulin inhibitor 51 neoadjuvant therapy 51 lung cancers 51 breast carcinoma 51 neurofibromas 51 cervical lymph nodes 51 Castration Resistant Prostate Cancer 51 PCa 51 aHUS 51 BRAF V#E 51 carcinoid cancer 51 malignant ovarian 51 advanced adenoma 51 gastric cancer 51 colon pancreatic 51 Pleural mesothelioma 51 chronic periodontitis 51 lung colorectal 51 IDH1 mutations 51 premalignant lesions 51 pediatric acute lymphoblastic 51 advanced adenomas 51 FLT3 51 Systemic lupus erythematosus 51 invasive ductal carcinoma 51 Chronic insomnia 51 Malignant melanoma 51 Prostatitis 51 chemotherapeutic regimens 51 BRAF gene 51 Candida infections 51 cell lymphomas 51 breast ovarian 51 breast pancreatic 51 leukemia myeloma 51 estrogen receptor positive 51 Paraplatin ® carboplatin 51 rhinosinusitis 51 BRAF mutations 51 hematological cancers 51 autoimmune thyroiditis 51 metastatic prostate cancer 51 pathologic myopia 51 Malignant mesothelioma 51 TTR gene 51 situ LCIS 51 HER2 positivity 51 Adjuvant chemotherapy 51 cancer mCRC 51 hematological disorders 51 relapsed GBM 51 fungoides 51 transfusion syndrome 51 oral squamous cell 51 undergone radical prostatectomy 51 Chronic Myelogenous Leukemia 51 adenomyosis 51 lymphoid tumors 51 cranial irradiation 50 carcinomatosis 50 complete remissions 50 premalignant 50 HoFH 50 cytoreduction 50 myeloid metaplasia 50 follicular thyroid cancer 50 chronic hepatitis B. 50 recurrent glioma 50 ara C 50 paraganglioma 50 lymphoma subtypes 50 Metastatic Colorectal Cancer 50 epirubicin 50 axillary node dissection 50 Brain metastases 50 KIT mutations 50 pre cancerous lesions 50 squamous cell skin 50 superficial basal cell carcinoma 50 estrogen receptor progesterone receptor 50 MPS VI 50 commercialize deforolimus 50 myeloid leukemia 50 huN# DM1 50 complete cytogenetic response 50 BRCA1 mutation carriers 50 cediranib 50 Malignant Glioma 50 Ankylosing spondylitis 50 fallopian tube carcinoma 50 myelodysplastic syndromes MDS 50 colorectal cancers 50 chronic ITP patients 50 HBeAg positive 50 Irinotecan 50 cutaneous T 50 CTEPH 50 Wet macular degeneration 50 malignant prostate 50 Critical limb ischemia 50 kidney urologic 50 retinal diseases 50 proliferative retinopathy 50 mCRC patients 50 riociguat 50 T2DM 50 deletion 5q 50 simplex virus 50 systemic lupus erythematosus 50 posterior uveitis 50 endometrioid 50 thrombocytopenic 50 advanced medullary thyroid 50 Bezielle 50 leukemia CML 50 Coeliac disease 50 grade dysplasia 50 allogeneic bone marrow 50 Li Fraumeni Syndrome 50 allogeneic HSCT 50 cranial radiation 50 receptor tyrosine kinase inhibitor 50 cisplatin chemotherapy 50 Adenomas 50 Gastric cancer 50 Solid Tumors 50 metastatic HER2 negative 50 gefitinib Iressa 50 papillary carcinoma 50 immunosuppressed patients 50 immunocompetent 50 hepatic fibrosis 50 KRAS status 50 hypoxia inducible factor 50 thrombocytopenic patients 50 Parkinson Disease PD 50 unresectable locally advanced 50 sorafenib Nexavar 50 Telintra 50 tumor recurrence 50 HER2 positive breast 50 Chronic Lymphocytic Leukemia 50 squamous histology 50 monogenic 50 HRPC 50 SSc 50 chronic rhinosinusitis 50 taxane therapy 50 Meningiomas usually occur 50 medically inoperable 50 overexpress HER2 50 gemcitabine chemotherapy 50 transitional cell carcinoma 50 alemtuzumab treated 50 unresectable liver cancer 50 unfavorable cytogenetics 50 fibrotic disease 50 basal cell cancers 50 proliferative disorders 50 KRAS mutations 50 FSGS 50 metastatic colorectal 50 GvHD 50 chronic hepatitis C. 50 CABG surgeries 50 adenomatous 50 invasive aspergillosis 50 nonalcoholic steatohepatitis 50 forodesine 50 KRAS mutant tumors 50 Acute Myeloid Leukemia AML 50 hematologic 50 CTAP# Capsules 50 glioblastoma multiforme tumors 50 Alemtuzumab 50 elacytarabine 50 axitinib 50 hormone receptor negative 50 Heavy menstrual bleeding 50 chronic eosinophilic leukemia 50 diagnosed glioblastoma multiforme 50 vascular abnormalities 50 Idiopathic Pulmonary Fibrosis 50 Wegener granulomatosis 50 neuroblastoma tumors 50 basal cell carcinomas 50 colorectal cancer liver metastases 50 CLL 50 sustained virological response 50 Calcineurin inhibitors 50 intracranial tumors 50 atypical ductal hyperplasia 50 MMP inhibitors 50 Doxil ® 50 Vidaza ® 50 Lupus nephritis 50 fatal neurodegenerative disorder 50 hematopoietic cell 50 C1 INH deficiency 50 IV NSCLC 50 precancerous tumors 50 radiation therapy SBRT 50 eosinophilic pneumonia 50 sorafenib tablets 50 epithelial ovarian cancer 50 VaD 50 brain tumor glioblastoma multiforme 50 Metastatic breast cancer 50 cirrhosis liver failure 50 lysosomal storage diseases 50 cell malignancies 50 axillary lymph nodes 50 lung tumors 50 pancreatic neuroendocrine tumors 50 Alessandro Riva 50 pheochromocytomas 50 Nothing Wadden 50 decitabine 50 fatal neurodegenerative 50 Acute Myeloid Leukaemia AML 50 Uterine cancer 50 diffuse gastric 50 vismodegib 50 carotid stenosis 50 carcinoids 50 Circulating tumor cells 50 FDG-PET/CT 50 lymphoblastic leukemia 50 Chronic ITP 50 Temporal lobe epilepsy 50 Medulloblastoma 50 Myelodysplastic Syndromes 50 lymphoid malignancies 50 Non Hodgkin lymphoma 50 epilepsies 50 Cell Lung Cancer 50 Wet AMD 50 axillary dissection 50 gemcitabine carboplatin 50 pancreatic endocrine 50 genital HPV 50 Toxicities 50 Rate ORR 50 breast tumors 50 CD# mAb 50 tumor metastases 50 molecular remissions 50 anticancer therapy 50 prophylactic cranial irradiation 50 cervical intraepithelial neoplasia 50 choriocarcinoma 50 faulty BRCA genes 50 imatinib Gleevec ® 50 Maroteaux Lamy syndrome 50 KRAS oncogene 50 estrogen receptor ER 50 urothelial carcinoma 50 myeloid 50 testicular tumors 50 penetrance 50 nonmelanoma skin cancer 50 moderately emetogenic 50 pulmonary metastases 50 lymphopenia 50 TORISEL 50 Sleep apnea affects 50 nonsense mutations 50 curative therapy 50 Prostate Cancer Prostate 50 VFEND 50 stage IIIb 50 chemoresistant 50 Brentuximab Vedotin SGN 50 precancerous lesions 50 estrogen receptor negative 50 Irritable bowel syndrome 50 T1DM 50 Acute Myelogenous Leukemia AML 50 splenectomized patients 50 myelomas 49 transthyretin amyloidosis 49 intravesical therapy 49 hemolytic anemia 49 Thyroid cancer 49 NF1 49 gemcitabine Gemzar 49 OncoVEX GM CSF 49 esophageal adenocarcinoma 49 BCR ABL mutations 49 pancreatic islet cell 49 PKCi 49 anti angiogenic drugs 49 decompensated liver disease 49 Testicular cancer 49 BCG refractory 49 papillary thyroid carcinoma 49 macroglobulinemia 49 neovascular diseases 49 INCB# [003] 49 activating mutation 49 CMV disease 49 Basal Cell 49 hormone refractory 49 symptomatic aortic stenosis 49 spontaneously regress 49 previously untreated follicular 49 non metastatic resectable 49 relapsing multiple sclerosis 49 colon carcinoma 49 Evoltra ® 49 AGTR1 49 idiopathic thrombocytopenic purpura ITP 49 cilengitide 49 chemotherapy cisplatin 49 melanoma basal cell 49 cryptococcosis 49 rectal cancers 49 Moyamoya disease 49 melanoma 49 AMN# [001] 49 Tumours 49 radiochemotherapy 49 basal cell cancer 49 ductal cancer 49 motor neuron diseases 49 normal karyotype 49 refractory Hodgkin lymphoma 49 Neuvenge 49 papillary thyroid cancer 49 T#I mutant 49 Diabetic nephropathy 49 Extensively drug 49 Xanafide 49 colorectal pancreatic 49 breast colorectal 49 glomerulonephritis 49 autoimmune hemolytic anemia 49 hereditary antithrombin deficiency 49 EGFr 49 tyrosine kinase inhibitors TKIs 49 Generalized anxiety disorder 49 epithelial ovarian 49 refractory AML 49 dermatologic reactions 49 INC# 49 ATTR PN 49 metastatic uveal melanoma 49 TheraSphere 49 heavily pretreated patients 49 Schizophrenia affects 49 paroxysmal nocturnal hemoglobinuria PNH 49 Atopic eczema 49 neoadjuvant chemotherapy 49 embryonal 49 Aortic stenosis 49 PSADT 49 Peritoneal mesothelioma 49 demonstrated antitumor activity 49 Acute myelogenous leukemia 49 CTCL 49 K ras 49 non Hodgkin lymphoma 49 Fludarabine 49 relapsed multiple myeloma 49 Peginterferon alfa 2b 49 esophagitis 49 Pulmonary hypertension 49 malignant neoplasms 49 cell lymphoma ALCL 49 adriamycin 49 Squamous cell 49 TKI therapy 49 Advanced Renal Cell 49 Barrett mucosa 49 idarubicin 49 thyrotoxicosis 49 sentinel nodes 49 acoustic neuromas 49 certolizumab 49 paclitaxel cisplatin 49 SIR Spheres microspheres 49 heart valve insufficiency 49 anaplastic astrocytomas 49 refractory CLL 49 H. pylori infections 49 glioma rarer 49 cytokine refractory 49 liver scarring 49 B Cell Lymphoma 49 malignant growths 49 irritable bowel syndrome IBS 49 hematologic toxicity 49 CCyR 49 HBeAg negative 49 Benign prostatic hyperplasia BPH 49 gynecologic malignancy 49 thyroiditis